## Salvatore De Vita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4821228/publications.pdf

Version: 2024-02-01

94 papers 2,536 citations

201575 27 h-index 214721 47 g-index

97 all docs 97
docs citations

97 times ranked 3468 citing authors

#	Article	IF	CITATIONS
1	Arthritis Interception in Patients with Psoriasis Treated with Guselkumab. Dermatology and Therapy, 2022, 12, 5-8.	1.4	7
2	Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet, The, 2022, 399, 161-171.	6.3	72
3	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. Computational and Structural Biotechnology Journal, 2022, 20, 471-484.	1.9	7
4	Safety, patient acceptance and diagnostic accuracy of ultrasound core needle biopsy of parotid or submandibular glands in primary SjĶgren's syndrome with suspected salivary gland lymphoma. RMD Open, 2022, 8, e001901.	1.8	4
5	Asymptomatic sacroiliitis detected by magnetic resonance enterography in patients with Crohn's disease: prevalence, association with clinical data, and reliability among radiologists in a multicenter study of adult and pediatric population. Clinical Rheumatology, 2022, 41, 2499-2511.	1.0	3
6	High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. Journal of Autoimmunity, 2022, 129, 102827.	3.0	19
7	Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response―by Verhoeven et al. Joint Bone Spine 2021;88:105258. Joint Bone Spine, 2022, , 105408.	0.8	1
8	Sjögren syndrome: looking forward to the future. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211002.	1.2	10
9	Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases. Internal and Emergency Medicine, 2021, 16, 581-589.	1.0	11
10	Influenza vaccination in chronic inflammatory arthritis undergoing immunosuppressive treatments: temporal trend and factors of adherence. Rheumatology, 2021, 60, 2456-2460.	0.9	1
11	Answer to Vieira et al. "Cytokine profile as a prognostic tool in coronavirus disease 2019― Joint Bone Spine 2020. Doi:10.1016/j.jbspin.2020.09.006. Joint Bone Spine, 2021, 88, 105076.	0.8	2
12	Ultrasound-guided core needle biopsy compared with open biopsy: a new diagnostic approach to salivary gland enlargement in Sjögren's syndrome?. Rheumatology, 2021, 60, 1282-1290.	0.9	19
13	Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis. Rheumatology, 2021, 60, 3476-3477.	0.9	18
14	Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. Frontiers in Immunology, 2021, 12, 615656.	2.2	12
15	Ultrasound and Bioptic Investigation of Patients with Primary Sjögren's Syndrome. Journal of Clinical Medicine, 2021, 10, 1171.	1.0	10
16	Rheumatologic manifestations of Hepatitis C Virus. Minerva Medica, 2021, 112, 201-214.	0.3	7
17	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. Journal of Autoimmunity, 2021, 121, 102648.	3.0	24
18	Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 3773.	1.0	6

#	Article	lF	Citations
19	An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis: The SIRENA Study. Frontiers in Medicine, 2021, 8, 711875.	1.2	3
20	NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. Frontiers in Immunology, 2021, 12, 706737.	2.2	8
21	Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. Rheumatology and Therapy, 2021, 8, 1519-1534.	1.1	42
22	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. Journal of Autoimmunity, 2021, 124, 102729.	3.0	23
23	Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110406.	1.2	11
24	Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts. Frontiers in Immunology, 2021, 12, 672255.	2.2	6
25	The Digital Way to Intercept Psoriatic Arthritis. Frontiers in Medicine, 2021, 8, 792972.	1.2	3
26	Magnetic resonance imaging assessment of ASAS-defined active sacroiliitis in patients with inflammatory back pain and suspected axial spondyloarthritis: a study of reliability. Clinical and Experimental Rheumatology, 2021, 39, 1331-1337.	0.4	1
27	Sonographic features of lymphoma of the major salivary glands diagnosed with ultrasound-guided core needle biopsy in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.4	1
28	Patient-reported experience and health-related quality of life in patients with primary Sj $\tilde{A}$ ¶gren's syndrome in Europe. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
29	Patient-reported experience and health-related quality of life in patients with primary Sjögren's syndrome in Europe. Clinical and Experimental Rheumatology, 2021, 39, 123-130.	0.4	1
30	Sonographic features of lymphoma of the major salivary glands diagnosed with ultrasound-guided core needle biopsy in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 175-183.	0.4	12
31	Data linkage analysis of giant cell arteritis in Italy: Healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001–2017). Vascular Medicine, 2020, 25, 150-156.	0.8	9
32	Sjögren's Syndrome: The Clinical Spectrum of Male Patients. Journal of Clinical Medicine, 2020, 9, 2620.	1.0	26
33	Salivary Gland Ultrasonography in Sjögren's Syndrome: A European Multicenter Reliability Exercise for the HarmonicSS Project. Frontiers in Medicine, 2020, 7, 581248.	1.2	26
34	Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. Frontiers in Immunology, 2020, 11, 594096.	2.2	45
35	Efficacy and Safety of High-Dose Immunoglobulin-Based Regimen in Statin-Associated Autoimmune Myopathy: A Multi-Center and Multi-Disciplinary Retrospective Study. Journal of Clinical Medicine, 2020, 9, 3454.	1.0	10
36	Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. Journal of Clinical Virology, 2020, 129, 104444.	1.6	147

#	Article	IF	CITATIONS
37	Higher levels of ILâ€6 early after tocilizumab distinguish survivors from nonsurvivors in COVIDâ€19 pneumonia: A possible indication for deeper targeting of ILâ€6. Journal of Medical Virology, 2020, 92, 2852-2856.	2.5	52
38	NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium. Scientific Reports, 2020, 10, 4316.	1.6	14
39	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	1.2	21
40	Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine, 2020, 87, 191-193.	0.8	45
41	Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine, 2020, 87, 439-443.	0.8	71
42	Rheumatoid factor-producing CD21low anergic clonal B-cells in essential mixed cryoglobulinaemia: a model for autoantigen-driven pathogenesis of infectious and non-infectious cryoglobulinaemias. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 139-147.	0.4	1
43	Significance of anti-La/SSB antibodies in primary Sjögren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 53-56.	0.4	O
44	Ultrasound assessment of lacrimal glands: a cross-sectional study in healthy subjects and a preliminary study in primary SjĶgren's syndrome patients. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 203-209.	0.4	0
45	Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 189-194.	0.4	O
46	Predicting lymphoma development in patients with Sjögren's syndrome. Expert Review of Clinical Immunology, 2019, 15, 929-938.	1.3	31
47	Emerging drugs for primary Sjögren's syndrome. Expert Opinion on Emerging Drugs, 2019, 24, 121-132.	1.0	10
48	Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors. Frontiers in Immunology, 2019, 10, 1527.	2.2	5
49	234.â€∱ANCA-ASSOCIATED VASCULITIS AND WORK ABILITY: EVALUATION OF DISEASE IMPACT ON WORKING LIFAS AN OUTCOME MEASURE IN A MONOCENTRIC ITALIAN COURT. Rheumatology, 2019, 58, .	FE 0.9	1
50	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. Frontiers in Pharmacology, 2019, 10, 918.	1.6	25
51	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	1.6	35
52	Medical data quality assessment: On the development of an automated framework for medical data curation. Computers in Biology and Medicine, 2019, 107, 270-283.	3.9	67
53	AB0166â€ENHANCING THE QUALITY OF CLINICAL DATA THROUGH DATA CURATION IN PRIMARY SJ¶GREN' SYNDROME. , 2019, , .	MS	0
54	SATO190â€LYMPHOMA IN PRIMARY SJÖGREN'S SYNDROME: A RETROSPECTIVE CLINICAL STUDY WITH PAFROM THE UPA (UDINE, PISA, ATHENS) GROUP. , 2019, , .	TIENTS	0

#	Article	IF	CITATIONS
55	Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open, 2019, 5, e001067.	1.8	56
56	Seronegative Arthritis and Whipple Disease: Risk of Misdiagnosis in the Era of Biologic Agents. Case Reports in Rheumatology, 2019, 2019, 1-6.	0.2	8
57	The ultrasonographic study of the nail reveals differences in patients affected by inflammatory and degenerative conditions. Clinical Rheumatology, 2019, 38, 913-920.	1.0	25
58	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews, 2019, 18, 93-106.	2.5	101
59	Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. Pharmacogenomics Journal, 2019, 19, 83-96.	0.9	10
60	Ultrasonographic detection of subclinical enthesitis and synovitis: a possible stratification of psoriatic patients without clinical musculoskeletal involvement. Clinical and Experimental Rheumatology, 2019, 37, 593-599.	0.4	19
61	Enhancing medical data quality through data curation: a case study in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 90-96.	0.4	2
62	Sjögren's syndrome towards precision medicine: the challenge of harmonisation and integration of cohorts. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 175-184.	0.4	4
63	Thymic stromal lymphopoietin expression from benign lymphoproliferation to malignant B-cell lymphoma in primary SjĶgren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 55-64.	0.4	2
64	Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 199-208.	0.4	9
65	Early Psoriatic Arthritis Versus Early Seronegative Rheumatoid Arthritis: Role of Dermoscopy Combined with Ultrasonography for Differential Diagnosis. Journal of Rheumatology, 2018, 45, 648-654.	1.0	33
66	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	1.0	64
67	Retrospective analysis of the usefulness of a protocol with highâ€dose methotrexate in polymyalgia rheumatica: Results of a singleâ€center cohort of 100 patients. Geriatrics and Gerontology International, 2018, 18, 1410-1414.	0.7	6
68	Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 107-114.	0.4	11
69	Dermoscopy as a supportive tool in differential diagnosis of psoriatic arthritis: another reason to include such a technique in rheumatology fellow curriculum. Clinical and Experimental Rheumatology, 2018, 36, 514.	0.4	0
70	Imaging in primary Sj $ ilde{A}$ ¶gren's syndrome: the 'obsolete and the new'. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 215-221.	0.4	12
71	The evaluation of disease activity in Sjögren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 150-156.	0.4	7
72	Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection. Expert Review of Clinical Pharmacology, 2017, 10, 1085-1101.	1.3	6

#	Article	IF	Citations
73	Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in SjĶgren's syndrome. Clinical and Experimental Rheumatology, 2017, 35, 719-720.	0.4	3
74	HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC). Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 67-76.	0.4	9
75	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	1.6	72
76	Dermoscopy of nail fold and elbow in the differential diagnosis of early psoriatic arthritis sine psoriasis and early rheumatoid arthritis. Journal of Dermatology, 2016, 43, 1217-1220.	0.6	23
77	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Annals of the Rheumatic Diseases, 2016, 75, 1945-1950.	0.5	57
78	Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology, 2016, 55, 1443-1451.	0.9	51
79	Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. Journal of Autoimmunity, 2015, 63, 88-93.	3.0	41
80	Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. Rheumatology, 2015, 54, kev257.	0.9	66
81	Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Annals of the Rheumatic Diseases, 2015, 74, 526-531.	0.5	248
82	Myositis in primary Sjögren's syndrome: data from a multicentre cohort. Clinical and Experimental Rheumatology, 2015, 33, 457-64.	0.4	27
83	Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology, 2014, 53, 2209-2213.	0.9	67
84	The classification criteria for Sj $\tilde{A}$ ¶gren syndrome: issues for their improvement from the study of a large Italian cohort of patients. Annals of the Rheumatic Diseases, 2014, 73, e35-e35.	0.5	6
85	Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. Autoimmunity Reviews, 2014, 13, 609-614.	2.5	37
86	Golimumab: A Novel Anti-Tumor Necrosis Factor. Biologics in Therapy, 2013, 3, 83-107.	1.8	6
87	Treatment of mixed cryoglobulinemia: a rheumatology perspective. Clinical and Experimental Rheumatology, 2011, 29, S99-103.	0.4	2
88	Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Digestive and Liver Disease, 2007, 39, S122-S128.	0.4	32
89	Treatment of rheumatoid arthritis with rituximab: An update and possible indications. Autoimmunity Reviews, 2006, 5, 443-448.	2.5	33
90	Lack of Hcv Infection in Malignant, Cells Refutes the Hypothesis of a Direct Transforming Action of the Virus in the Pathogenesis of Hcv-Associated B-Cell Nhls. Tumori, 2002, 88, 400-406.	0.6	21

#	Article	IF	CITATIONS
91	Lack of HCV infection in malignant cells refutes the hypothesis of a direct transforming action of the virus in the pathogenesis of HCV-associated B-cell NHLs. Tumori, 2002, 88, 400-6.	0.6	6
92	True primary Sj $\tilde{A}$ ¶gren's syndrome in a subset of patients with hepatitis C infection: a model linking chronic infection to chronic sialadenitis. Israel Medical Association Journal, 2002, 4, 1101-5.	0.1	38
93	Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. International Journal of Cancer, 2000, 87, 211-216.	2.3	125
94	Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus–associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor–producing cells that occur mainly in type II cryoglobulinemia. Blood, 2000, 96, 3578-3584.	0.6	205